` Comparison: CTNM vs 512038 - Alpha Spread

C
CTNM
vs
A
512038

Over the past 12 months, CTNM has significantly outperformed TCC, delivering a return of +57% compared to the TCC's 19% drop.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
CTNM
512038
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

C
CTNM Intrinsic Value
2.64 USD
Overvaluation 78%
Intrinsic Value
Price
A
TCC Intrinsic Value
196.78 INR
Overvaluation 45%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
C
Contineum Therapeutics Inc
NASDAQ:CTNM
12.21 USD
A
Aaswa Trading and Exports Ltd
BSE:512038
357.15 INR
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
CTNM, 512038

CTNM
512038
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
C
Contineum Therapeutics Inc
Revenue
A
Aaswa Trading and Exports Ltd
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
CTNM, 512038

CTNM
512038
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
C
Contineum Therapeutics Inc
NASDAQ:CTNM
A
Aaswa Trading and Exports Ltd
BSE:512038
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

CTNM
0%
TCC
90.6%

Operating Margin

CTNM
0%
TCC
52.7%

Net Margin

CTNM
0%
TCC
39.8%

FCF Margin

CTNM
0%
TCC
-110.8%

ROE

CTNM
-29.2%
TCC
7.1%

ROA

CTNM
-28.1%
TCC
6.6%

ROIC

CTNM
-1 791.7%
TCC
7.4%

ROCE

CTNM
-33.6%
TCC
9.1%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
CTNM, 512038

Loading
CTNM
512038
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CTNM, 512038

Loading
CTNM
512038
Difference
www.alphaspread.com

Performance By Year
CTNM, 512038

Loading
CTNM
512038
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare CTNM to other stocks
GEV
GE Vernova LLC
G
More expensive
vs CTNM
ECS
Eight Capital Partners PLC
E
More expensive
vs CTNM
CIND
China Industrial Group Inc
C
More expensive
vs CTNM
NRP
Nepi Rockcastle NV
N
Cheaper
vs CTNM
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett